Yang W, Jing T, Wu C, Lu M, Yao X, Xia D
J Transl Med. 2025; 23(1):335.
PMID: 40089779
DOI: 10.1186/s12967-025-06356-y.
Wang F, Li L, Sun X, Cai X, Wang J, Luo H
Cell Death Discov. 2025; 11(1):97.
PMID: 40074730
PMC: 11903659.
DOI: 10.1038/s41420-025-02385-0.
Zhang D, Shen C, Zhang W, Chen H, Zhao J
Front Immunol. 2025; 16:1524497.
PMID: 40070839
PMC: 11893867.
DOI: 10.3389/fimmu.2025.1524497.
Pan Y, Liu S, Shu G, Chen M, Fu L, Chen C
Cell Death Dis. 2025; 16(1):125.
PMID: 39988631
PMC: 11847927.
DOI: 10.1038/s41419-025-07456-9.
Li X, Lin D, Xiong Y, Lin W, Zhang S, Huang S
Eur Radiol. 2025; .
PMID: 39979621
DOI: 10.1007/s00330-025-11446-y.
Organoids as Sophisticated Tools for Renal Cancer Research: Extensive Applications and Promising Prospects.
Huang J, Wang X, Ge S, Lu X, Sun C
Cell Mol Bioeng. 2025; 17(6):527-548.
PMID: 39926385
PMC: 11799493.
DOI: 10.1007/s12195-024-00825-y.
Liquid biopsy for Renal Cell Carcinoma: A comprehensive review of techniques, applications, and future prospects.
Jani C, Abdallah N, Tan A, McKay R
Kidney Cancer. 2025; 8(1):205-225.
PMID: 39886007
PMC: 11781563.
DOI: 10.1177/24684570241303346.
Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction.
Lyu F, Zhong Y, He Q, Xiao W, Zhang X
BMC Cancer. 2025; 25(1):148.
PMID: 39871215
PMC: 11771106.
DOI: 10.1186/s12885-025-13534-0.
Endogenous peptide CBDP1 inhibits clear cell renal cell carcinoma progression by targeting USP5/YTHDF2/TRPM5 axis.
Zhang Y, Zhu W, Tao R, Li W, Jiang C, Yan X
J Transl Med. 2025; 23(1):116.
PMID: 39863860
PMC: 11763126.
DOI: 10.1186/s12967-025-06091-4.
Complement C3 of tumor-derived extracellular vesicles promotes metastasis of RCC via recruitment of immunosuppressive myeloid cells.
Zhang Y, Wang X, Gu Y, Liu T, Zhao X, Cheng S
Proc Natl Acad Sci U S A. 2025; 122(4):e2420005122.
PMID: 39847320
PMC: 11789090.
DOI: 10.1073/pnas.2420005122.
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes.
Xu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler N
ESMO Open. 2025; 10(2):104105.
PMID: 39813824
PMC: 11783098.
DOI: 10.1016/j.esmoop.2024.104105.
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial.
Msaouel P, Yu K, Yuan Y, Chen J, Yan X, Karki M
Nat Commun. 2025; 16(1):578.
PMID: 39794332
PMC: 11724043.
DOI: 10.1038/s41467-024-55642-8.
CASP5 associated with PANoptosis promotes tumorigenesis and progression of clear cell renal cell carcinoma.
Yang K, Wang Y, Jian Y, Wang B, Du H, Xia Y
Cancer Cell Int. 2025; 25(1):8.
PMID: 39780201
PMC: 11716502.
DOI: 10.1186/s12935-024-03630-9.
Exploring the Prognostic Value of Tumour-Associated Genes in Clear Cell Renal Cell Carcinoma Through Single-Cell RNA Sequencing Insights.
Fu T, Zhang X, Liu Y, Wu J, Liu X, Lu B
J Cell Mol Med. 2024; 28(24):e70297.
PMID: 39706820
PMC: 11661917.
DOI: 10.1111/jcmm.70297.
Management of translocation carcinomas of the kidney.
Ged Y, Feinaj A, Baraban E, Singla N
Transl Cancer Res. 2024; 13(11):6438-6447.
PMID: 39697715
PMC: 11651741.
DOI: 10.21037/tcr-24-60.
The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma.
Narukawa T, Yasuda S, Horinaka M, Taniguchi K, Tsujikawa T, Morita M
Cancers (Basel). 2024; 16(23).
PMID: 39682244
PMC: 11640654.
DOI: 10.3390/cancers16234058.
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.
Choueiri T, Kuzel T, Tykodi S, Verzoni E, Kluger H, Nair S
ESMO Open. 2024; 9(12):104073.
PMID: 39642635
PMC: 11667034.
DOI: 10.1016/j.esmoop.2024.104073.
SiRCle (Signature Regulatory Clustering) model integration reveals mechanisms of phenotype regulation in renal cancer.
Mora A, Schmidt C, Balderson B, Frezza C, Boden M
Genome Med. 2024; 16(1):144.
PMID: 39633487
PMC: 11616309.
DOI: 10.1186/s13073-024-01415-3.
Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database.
Lee C, Kang M, Kwak C, Ko Y, Kim J, Park J
J Korean Med Sci. 2024; 39(45):e293.
PMID: 39592128
PMC: 11596476.
DOI: 10.3346/jkms.2024.39.e293.
Tissue factor pathway inhibitor 2 (TFPI2) is a potential serum biomarker for clear cell renal carcinoma.
Ito H, Jikuya R, Myoba S, Tatenuma T, Noguchi G, Ueno D
Sci Rep. 2024; 14(1):28639.
PMID: 39562727
PMC: 11576975.
DOI: 10.1038/s41598-024-80248-x.
